Patent application number | Description | Published |
20120204275 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 08-09-2012 |
20130108546 | Humanized Antibodies That Recognize Alpha-Synuclein | 05-02-2013 |
20130266517 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease. | 10-10-2013 |
20140050733 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 02-20-2014 |
20140127131 | ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN - The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA). | 05-08-2014 |
20140275495 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease. | 09-18-2014 |
20140348843 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 11-27-2014 |
20150024433 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease. | 01-22-2015 |
20150056187 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease. | 02-26-2015 |